Literature DB >> 7129644

Concentrations of amphotericin B in faeces and blood of healthy volunteers after the oral administration of various doses.

W Hofstra, H G de Vries-Hospers, D van der Waaij.   

Abstract

We have investigated which dose of amphotericin B can be regarded as an optimal oral dose for the prophylaxis of colonization of the digestive tract by Candida species. Ten human volunteers were given different doses; each dose was administered for five days. The results of this study revealed that although oral doses of 0.5 g amphotericin B per day resulted in sufficient concentrations in 70% of the faecal samples obtained during application, higher doses (1.5 or 2 g per day) were required to obtain detectable amphotericin B activity in 95% and 100% of the samples, respectively. A daily dose of 1.0 g is recommended. We have taken into consideration the variation in amphotericin B concentrations among individuals following this recommended dose.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7129644     DOI: 10.1007/bf01666915

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  11 in total

1.  Some aspects of the absorption, distribution, and excretion of amphotericin B in man.

Authors:  D B LOURIA
Journal:  Antibiotic Med Clin Ther (New York)       Date:  1958-05

2.  A comparative trial of tobramycin vs gentamicin in combination with vancomycin and nystatin for alimentary tract suppression in leukemic patients.

Authors:  J F Bender; S C Schimpff; V M Young; C L Fortner; L J Love; M D Brouillet; P H Wiernik
Journal:  Eur J Cancer       Date:  1979       Impact factor: 9.162

3.  Infections in cancer patients on a protected environment-prophylactic antibiotic program.

Authors:  G P Bodey; V Rodriguez
Journal:  Am J Med       Date:  1975-10       Impact factor: 4.965

Review 4.  Opportunistic invasive fungal infections in patients with leukaemia lymphoma.

Authors:  J A Krick; J S Remington
Journal:  Clin Haematol       Date:  1976-06

5.  Infection prevention in granulocytopenic patients by selective decontamination of the digestive tract.

Authors:  D T Sleijfer; N H Mulder; H G de Vries-Hospers; V Fidler; H O Nieweg; D van der Waaij; H K van Saene
Journal:  Eur J Cancer       Date:  1980-06       Impact factor: 9.162

6.  Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens.

Authors:  S C Schimpff; V M Young; W H Greene; G D Vermeulen; M R Moody; P H Wiernik
Journal:  Ann Intern Med       Date:  1972-11       Impact factor: 25.391

7.  Partial antibiotic decontamination.

Authors:  H F Guiot; R Furth
Journal:  Br Med J       Date:  1977-03-26

8.  Infection by the distribution of biotypes of enterobacteriacease species in leukaemic patients treated under ward conditions and in units for protective isolation in seven hospitals in Europe.

Authors:  D Van der Waaij; T M Tielemans-Speltie; A M De Roeck-Houben
Journal:  Infection       Date:  1977       Impact factor: 3.553

9.  Infection prevention in acute nonlymphocytic leukemia. Laminar air flow room reverse isolation with oral, nonabsorbable antibiotic prophylaxis.

Authors:  S C Schimpff; W H Greene; V M Young; C L Fortner; N Cusack; J B Block; P H Wiernik
Journal:  Ann Intern Med       Date:  1975-03       Impact factor: 25.391

10.  Concentrations of nystatin in faeces after oral administration of various doses of nystatin.

Authors:  W Hofstra; H G de Vries-Hospers; D van der Waaij
Journal:  Infection       Date:  1979       Impact factor: 3.553

View more
  6 in total

Review 1.  Antifungal prophylaxis during neutropenia and immunodeficiency.

Authors:  O Lortholary; B Dupont
Journal:  Clin Microbiol Rev       Date:  1997-07       Impact factor: 26.132

2.  Clinical use of selective decontamination: the concept.

Authors:  D van der Waaij; W L Manson; J P Arends; H G de Vries-Hospers
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

3.  Synergistic enhancement of parasiticidal activity of amphotericin B using copaiba oil in nanoemulsified carrier for oral delivery: an approach for non-toxic chemotherapy.

Authors:  Pramod K Gupta; Anil K Jaiswal; Shalini Asthana; Venkatesh Teja B; Prashant Shukla; Minakshi Shukla; Neeti Sagar; Anuradha Dube; Srikanta K Rath; Prabhat R Mishra
Journal:  Br J Pharmacol       Date:  2015-05-19       Impact factor: 8.739

Review 4.  Fungal infections in patients with neutropenia: challenges in prophylaxis and treatment.

Authors:  R Herbrecht; S Neuville; V Letscher-Bru; S Natarajan-Amé; O Lortholary
Journal:  Drugs Aging       Date:  2000-11       Impact factor: 3.923

Review 5.  Selective decontamination of the digestive tract: the mechanism of action is control of gut overgrowth.

Authors:  Luciano Silvestri; Miguel A de la Cal; Hendrick K F van Saene
Journal:  Intensive Care Med       Date:  2012-09-22       Impact factor: 17.440

Review 6.  Selective Intestinal Decontamination as a Method for Preventing Infectious Complications (Review).

Authors:  A L Barsuk; E S Nekaeva; L V Lovtsova; A L Urakov
Journal:  Sovrem Tekhnologii Med       Date:  2020-12-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.